Comparison of effectiveness of intravitreal ranibizumab and dexamethasone in branch retinal vein occlusion

Basit Öğe Kaydı
dc.contributor.authorCoskun, M.
dc.contributor.authorToklu, Y.
dc.date.accessioned2024-09-29T16:22:31Z
dc.date.available2024-09-29T16:22:31Z
dc.date.issued2020
dc.departmentKarabük Üniversitesien_US
dc.description.abstractPurpose: Comparison of intravitreal ranibizumab (IVR) and dexamethasone (IVD) effectiveness in branch retinal vein occlusion (BRVO) Materials and Methods: Fifty-five patients with BRVO and macular edema were treated with IVR (Group 1) in 32 patients and IVD (Group 2) in 23 patients. Groups were compared regarding age, gender, ischemia, duration of post-edema application, number of intravitreal injections. Intraocular pressures (IOP), central macular thickness (CMT) and logarithmic visual acuity (LVA) values were evaluated before injection and at months 1, 3 and 6 after injection. Statistical analyses were performed by SPSS 16.0. Results: Ischemia was present in 8 patients in group 1 and 13 patients in group 2 (p = 0.005). The mean number of injections was 2.41 ± 1.15 in group 1 and 1.66 ± 0.48 in group 2 (p = 0.007). The IOP was significantly higher at month 6 in group 1 (p = 0.018) and at month 3 in group 2 (p = 0.049). There was no statistical difference between LVA 3 and LVA 6 in group 1 (p=0.238). Among other parameters, there was significantly higher visual acuity level (p <0.05) with improvements up to 6 months. Although there was no statistical difference between LVA 1 and LVA 3 (p = 0.097) and between LVA 3 and LVA 6 (p = 0.397) in group 2, the visual acuity was progressively improved until month 6. There was statistically significant difference among other CMT values (p <0.05), although there was no statistical difference between CMT 3 and CMT 6 in Group 1 (p = 0.238). In group 2, there was no significant difference between CMT 1 and CMT 6 or CMT 3 and CMT 6 (p values 0.985, 0.414) but there were significant differences among other CMT values w (P <0.05). Conclusion: The intraocular pressure was found to be elevated in IVR group at month 6 and in IVD group at month 3. LVA remained low until month 6. While CMT was progressively decreased in the IVR group until month 6, it was decreased at month 1 followed by elevation at month 3 and further decreased at month 6 in the IVD group. © 2019 Gazi Eye Foundation. All rights reserved.en_US
dc.identifier.endpage12en_US
dc.identifier.issn1300-1256
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85094885460en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage6en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14619/10115
dc.identifier.volume28en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherGazi Eye Foundationen_US
dc.relation.ispartofRetina-Vitreusen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBranch vein occlusionen_US
dc.subjectDexamethasone implanten_US
dc.subjectIntravitreal injectionen_US
dc.subjectRanibizumaben_US
dc.titleComparison of effectiveness of intravitreal ranibizumab and dexamethasone in branch retinal vein occlusionen_US
dc.title.alternativeRetina Ven Dal Tıkanıklığında İntravitreal Ranibizumab ve Dexametazonun Etkinliğinin Karşılaştırılmasıen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu